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Somatic variation in mitochondrial DNA (mtDNA) has been described in primary breast tumors,
including single-nucleotide variants and variation in the number of mtDNA molecules per cell (mtDNA
content). However, there is currently a gap in the knowledge on the link between mitochondrial
variation in breast cancer cells and their phenotypic behavior (i.e., tumorigenesis) or outcome. This
review focuses on recent findings on mtDNA content and mtDNA somatic mutations in breast cancer and
the potential biological impact and clinical relevance.Introduction
Our knowledge on the genetic makeup of breast cancer has been
rapidly expanded by massive parallel sequencing of primary tumor
specimens [1]. With this technique, major somatic alterations
including single-nucleotide variants, small insertions or deletions,
copy number variations and large structural variants have been
characterized in the tumor chromosomes. So far, almost 100
tumor-driving genes have been identified [1]. Also, mutational
signatures of base substitutions and rearrangements have been
identified, pinpointing the processes shaping breast cancer gen-
omes and paving the way toward new diagnostics and treatments
[e.g., poly ADP ribose polymerase (PARP) inhibitors for cases
carrying tumor genome signatures induced by defective homolo-
gous-recombination-based DNA double-strand break repair].
Often forgotten or overlooked in these findings is the mito-
chondrial DNA (mtDNA). Mitochondria are essential in multiple
cellular processes, with energy production and initiation of apo-
ptosis evident in the hallmarks of cancer [2]. mtDNA encodes
proteins essential for the oxidative phosphorylation system and
thus mitochondrial function. Nearly a century ago, the metabolic
switch from oxidative phosphorylation to fermentation of tumor
cells, even in the presence of oxygen, was described [3]. Despite the
widely recognized importance of mitochondria in cancer and the
role of mtDNA in mitochondrial function, so far only a few studiesCorresponding author: Weerts, Marjolein J.A. (m.weerts@erasmusmc.nl)
1202 www.drugdiscoverytoday.comhave explored mtDNA in large cohorts of human cancers [4–8].
This review focuses on recent findings on mtDNA content and
mtDNA somatic mutations in breast cancer and their potential
biological impact and clinical relevance.
mtDNA
Human mtDNA is gene-dense; it is only~17 000 base pairs in size
but encodes 13 proteins, as well as two ribosomal RNAs and 22
transfer RNAs functioning in the mitochondrial protein trans-
lation apparatus (gene density of 1 per ~0.45 kilobases). By
contrast, the 23 chromosomes of the nuclear DNA (nDNA)
comprise~3 billion base pairs and >20 000 genes (gene density
of 1 per~120 kilobases). Characteristic for mtDNA is that multi-
ple copies of mtDNA can reside in a single mitochondrion, and
that multiple mitochondria can reside in a single cell. As a
result, the number of mtDNA molecules per cell (mtDNA con-
tent) is highly variable between tissue types [9–11]. Generally,
the mtDNA content is dependent on the energy demand of a
cell; for example, skeletal muscle and liver cells (high energy
demand) harbor thousands of mtDNA molecules but blood
lymphocytes (lower energy demand) contain only hundreds
of mtDNA molecules [12]. This cell-type-specific mtDNA con-
tent is assumed to be fairly stable under physiological condi-
tions but can be altered by stress such as exogenous toxins [13]
or viral infection [14]. Also, the mutation rate of mtDNA is
several orders of magnitude higher than that of nDNA [15,16],1359-6446/ã 2019 Elsevier Ltd. All rights reserved.
https://doi.org/10.1016/j.drudis.2019.03.019
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polymerase (POLG) [4,17,18]. The polyploid nature of mtDNA
combined with its mutation rate invokes the concept of hetero-
plasmy – the state where genetically different mtDNA molecules
reside within a single cell or even within a single mitochondri-
on. Heteroplasmy patterns within an individual can differ be-
tween tissues [19–22] (Fig. 1), where a heteroplasmic mtDNA
variant can either be present in only one tissue within an
individual or in multiple tissues but at variable heteroplasmic
allele frequencies.
mtDNA changes in cancer
The mtDNA content among human cancers appears to be highly
variable (Fig. 2a). Increases and decreases in mtDNA content
compared with tumor-adjacent tissue have been described for
different tumor types [7]. With respect to mutations, somatic
single-nucleotide variants are more common than somatic small
insertions or deletions in the tumor mtDNA [4–6,8]. The major
process shaping the mutational signature of those single nucleo-
tide variants is replication-coupled [4], owing to the fidelity of
POLG, similar to the process shaping the germline mtDNA poly-
morphic variation. Among different tumor types the number of
somatic mtDNA single-nucleotide variants (mutational burden)
per tumor does not vary extensively (median between 0 and 3 per
tumor) (Fig. 2b), similar to the number of heteroplasmic mtDNA
variants in tissues within an individual (median between 1 and 4
per tissue) (Fig. 1). This is different compared with the nuclear
somatic mutational burden per tumor, where the median muta-Ce
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FIGURE 1
Number of somatic heteroplasmic mitochondrial DNA (mtDNA) variants across (n
(number per tissue per individual) within different tissue types obtained at autopsy
natural causes, 10.5% intoxication and 12.5% unclear or other) as published by Li et
allele frequency).tional burden varies roughly between 0.5 and 10 mutations per
megabase (dependent on tumor type) [23]. The mtDNA mutation-
al burden is thus in the order of 10- to 100-fold greater than the
nDNA mutational burden in human cancers (not taking into
account the mtDNA content). The somatic mtDNA variants in
primary tumors appear across the entire mtDNA. There is some
recurrence on certain positions, which can be explained by the
underlying mutational process (by POLG); but it cannot be ex-
cluded that mutational selection is involved giving selective ad-
vantage to certain positions. Besides the mtDNA content and
somatic mtDNA mutations, the mtDNA ‘common deletion’ has
also been studied in cancer. This 4977 base-pair deletion occurs at
recurring breakpoints within the mtDNA and is observed in several
diseases. Although this deletion has been detected in tumor speci-
mens, it is also frequently detected in non-neoplastic specimens
such as tumor-adjacent normal tissue or blood [24] and its occur-
rence has been related to human aging as well [25,26].
A definite link between changes in mtDNA content or somatic
mtDNA single-nucleotide variants and tumorigenesis or progres-
sion has never been established. In preclinical models depletion of
mtDNA in tumor cells yields increased and decreased in vitro
tumorigenic phenotypes [27–34], as well as gain and loss of
tumorigenic potential in in vivo mouse xenografts [33–38]. Only
recently has it been shown that the tumorigenic potential of cells
depleted of mtDNA is dependent on restoring functional oxidative
phosphorylation, via the acquisition of whole mitochondria and
their mtDNA from surrounding cells [37,39,40]. However, the
downregulation of oxidative phosphorylation has been associatedSk
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oncancerous) human tissue types. Somatic heteroplasmic mtDNA variants
 (causes of death: 32.2% cardiovascular-related, 23% traumatic injuries, 21.7%
 al. [22]. Heteroplasmy levels of variants not shown (between 0.5% and 94.5%
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FIGURE 2
Mitochondrial DNA (mtDNA) content and number of somatic mtDNA variants across human cancer types. (a) mtDNA content (log10 transformed) within
primary tumors as published by Reznik et al. [7] and (b) (heteroplasmic) somatic mtDNA variants (number per tumor per individual) within primary tumors as
published by Ju et al. [4]. Heteroplasmy levels of variants not shown (between 3% and 100% allele frequency).
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mutations in the mtDNA of primary tumors, only a minor propor-
tion (<1%) overlap with mutations associated with mitochondrial
disease and are thus known to affect mitochondrial function [4].
Examples exist in the literature where specific mtDNA variants
(mainly at homoplasmy) or specific haplotypes have been shown
to have an effect on tumorigenesis or metastatic potential in
model systems by disrupting oxidative phosphorylation [42–44]
(and reviewed in [45]). The occurrence of variants that disrupt1204 www.drugdiscoverytoday.comoxidative phosphorylation (present either at hetero- or homo-
plasmy) has to date not been evaluated in large cohorts of human
tumor specimens. It appears that mtDNA changes can act as a
modifier in tumor cells. Heteroplasmy levels complicate interpre-
tation of mtDNA changes detected in human tumor specimens.
Negative selection on mtDNA mutations that potentially damage
mitochondrial activity (e.g., protein truncating) has been de-
scribed – nearly always present at heteroplasmy and seldom at
homoplasmy – whereas mutations that appear to have no effect on
Drug Discovery Today Volume 24, Number 5 May 2019 REVIEWS
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Nevertheless, positive selection has also been described for somatic
variants in the tumor [8]. Thus, there currently remains a gap in
knowledge on somatic mtDNA variants and their biological sig-
nificance in tumor formation and/or progression.
Clinical relevance of mtDNA content in breast cancer
In breast cancer, current clinical practice applies traditional prog-
nostic markers [46] including age at diagnosis, tumor size, lymph
node status and tumor grade to classify individual primary breast
cancer patients for their risk of metastasizing and/or death [47–49],
and they are used to determine whether or not an individual
patient is advised to receive perioperative treatment. Moreover,
presence of the estrogen receptor (ER) and/or progesterone recep-
tor (PR), and amplification of ERBB2 (HER2) in the primary tumor,
classify patients in a certain risk group, but this particularly
provides indication for respectively endocrine and anti-HER2
therapy [50]. Primary breast cancer patients who classify as
high-risk based on the traditional clinicopathological markers
receive perioperative chemotherapy and/or endocrine treatment,
intended to eliminate potential micrometastases (curative set-
ting). Recently, for patients with an inconclusive risk score the
indication for perioperative systemic treatment can be based on
gene-expression profiling [51]. In metastatic breast cancer
patients, chemotherapy is also a major line of systemic treatment
intended to prolong life (palliative setting). Here, anthracycline-
based chemotherapy regimens are frequently given, although
taxane-based regimens are also commonly used [52]. In addition
to regimens consisting of traditional cytotoxic agents, also in the
metastatic setting, several lines of endocrine (combination) and/or
anti-HER2 treatment can be applied based on the presence of ER
and/or PR or ERBB2 amplification in the (metastatic) tumor [53–
55].
Numerous studies have explored new biomarkers that might
add to the currently available prognostic and predictive models in
breast cancer, whereas only a few addressed whether alterations in
mtDNA could be used for this purpose. A decrease in mtDNA
content is frequently observed in primary breast tumors when
compared with tumor-adjacent normal mammary epithelium
(70% of cases) [7,56–60]. No recurrent association has been
described between the mtDNA content in the primary tumor
and any of the traditional prognostic or predictive clinicopatho-
logical markers [7,56–64]. However, we have recently evaluated
the association between the expression of mtDNA in the primary
tumor and ER status and observed a positive association in two
independent (ERBB2 balanced) cohorts [65], indicating that met-
abolic differences might be present across breast cancer subtypes.
In line with this, downregulation of nuclear-encoded genes in-
volved in oxidative phosphorylation has been described for triple-
negative breast cancer [66]. Nuclear effects of estrogen through ER
on mtDNA transcription have been described (as reviewed in [67]),
where ER indirectly upregulates expression of the mitochondrial
transcription factor (TFAM). Our work has also shown that
patients with the lowest mtDNA content in the primary tumor
had a worse prognosis (10-year distant metastasis-free survival) in a
retrospective cohort of primary breast cancer patients with lymph-
node-negative disease who did not receive any perioperative
systemic therapy [62]. Additionally, patients with low mtDNAcontent showed an improved outcome to adjuvant anthracy-
cline-based chemotherapy in a retrospective cohort of lymph-
node-positive disease (distant metastasis-free survival in the cura-
tive setting) as well as to first-line anthracycline-based chemother-
apy in a retrospective cohort of patients with advanced disease
(progression-free survival in the palliative setting) [63]. This did
not apply to the patients treated with methotrexate-based chemo-
therapy in both settings [63]. These associations with outcome
were independent of the above-mentioned clinicopathological
markers [62,63]. The mechanisms underlying these associations
remain to be established. A possible explanation might be based on
the fact that anthracyclines induce severe oxidative stress [68] and
are known to accumulate in mitochondria, where they can inter-
calate and damage mtDNA [69], whereas methotrexate is an
antimetabolite, ultimately leading to inhibition of DNA synthesis,
and induces only low levels of oxidative stress [68]. Elimination of
damaged mtDNA has been described in response to oxidative stress
[70]. Hypothetically tumor cells with low mtDNA content are
more susceptible to stress induced to the mitochondria or mtDNA,
such as those induced by anthracyclines, than cells with high
mtDNA content. Other studies have also reported on breast cancer
patient disease-free or overall survival in relation to tumorous
mtDNA content [57,58,71,72], but those studies contained rather
heterogeneous groups with either relatively small sample sizes or
no information about systemic treatments administered, render-
ing interpretation and comparison between studies difficult. Larg-
er cohorts of uniformly treated patients are necessary to validate
these findings and to further unravel the clinical relevance of
mtDNA content – or expression – quantification in breast cancer.
Nevertheless, the putative link between low mtDNA content
and susceptibility to regimens that induce severe oxidative stress
in mitochondria is interesting. This phenomenon probably does
not typically apply to breast cancer but could also be of signifi-
cance to other human cancers treated with similar regimens.
Anthracyclines are also frequently used in the treatment of sarco-
ma and hematological malignancies, and these cancer types are
therefore of interest to evaluate the link between mtDNA content
in the tumor and outcome after chemotherapy. In addition,
platinum-based chemotherapy also induces oxidative stress and
changes to mtDNA [73,74], whereas bleomycin has been shown to
damage mtDNA more extensively than it does nDNA [73,75], and
thus also for these regimens mtDNA content is potentially a
predictive marker. To take this even a little further, we could
speculate that not only the tumor cells but also nontumor cells
with low mtDNA content are more susceptible to anthracyclines or
other regimens that induce severe oxidative stress. Interestingly,
the endocrine agent tamoxifen has been shown to inhibit mtDNA
replication and decrease the mtDNA content in the liver in in vivo
model systems [76], similar to antiretroviral therapy which is
known to decrease mtDNA content in peripheral blood cells of
HIV-infected patients [77,78]. This could mean that heterogeneity
in mtDNA content in nontumor cells might result in (i) intrain-
dividual specific side-effects because certain tissues with low
mtDNA content are affected to a larger extent and (ii) interindi-
vidual differences in toxicities experienced because some individ-
uals might be more susceptible to treatment side-effects because of
endogenous lower mtDNA content in their healthy tissues. Elabo-
rating on this, one can imagine that also nuclear effects on mtDNAwww.drugdiscoverytoday.com 1205
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and/or toxicity. Perhaps somatic variants in ESR1 that alter the ER
to be constitutively active also influence the nuclear effects on
mitochondrial expression.
Off note, the mtDNA content in peripheral blood of breast
cancer patients is higher compared with controls [79–82] and
decreased mtDNA content in peripheral blood was associated with
increased cancer-related fatigue in breast cancer patients [83].
However, because mtDNA content varies between cell types and
blood composition was not analyzed, it should be evaluated
whether the observed changes in mtDNA content reflect an alter-
ation in blood composition in patients versus controls or patients
suffering from cancer-related fatigue. Summarizing, we propose
that the frequently observed decrease in mtDNA content in breast
tumors, potentially mtDNA expression, but also mtDNA content
and/or expression in nontumor tissues, could be exploited to guide
chemotherapeutic regimen decision-making.
Somatic mtDNA variants in breast cancer
Somatic mtDNA variants are frequently observed in primary
breast tumors (70% of cases) [4,5,61,65]. Most of these variants
are single-nucleotide variants and not small insertions or dele-
tions. These variants are distributed along the entire mitochon-
drial genome, showing large heterogeneity among cases, and are
acquired independently of the three major mutational processes
shaping the nDNA within breast tumors [65]. So far, no somatic
mtDNA mutations that clearly affect breast cancer tumorigenesis
or progression have been described; however, some mtDNA
haplogroups have been described as modifiers for metastatic
potential [43,44].
No recurrent association has been described between the num-
ber of somatic mtDNA variants in the primary tumor and the
traditional prognostic or predictive clinicopathological markers
tumor size, lymph node status, tumor grade, ER and/or PR status,
or ERBB2 amplification status. However, an association between
the number of somatic variants within the primary breast tumor
and the age of diagnosis has been described [4,65,84]. An expla-
nation for this association is the presence of allele-specific varia-
tion among tissues within an individual [19–22], which has also
been associated with age [12]. Because the major process generat-
ing somatic variants as detected in tumor tissue also appears to be
caused by the fidelity of the mitochondrial polymerase [4,65], the
association with an older age implies that a large amount of the
somatic variants detected in the tumor specimen are probably not
tumor-acquired but already present or acquired in the normal
mammary epithelial cell from which the tumor originated. Often
no matched mammary epithelial tissue is available, so the distinc-
tion between somatic variants acquired in the mammary epithelial
cells before cancer initiation and those truly acquired in the tumor
cells cannot be made. This is a limitation frequently overlooked.
Matched normal material commonly used in studies is blood, but
(somatic) variants in blood are unlikely to adequately reflect the
somatic mtDNA status in the mammary epithelial tissue from
which the cancer arose. In addition, the tumor specimen com-
monly contains not only tumor cells but also other cells such as
surrounding epithelial cells or immune cells infiltrating the tumor.
In line with the allele-specific variation among tissues within an
individual, we have shown extensive mtDNA heterogeneity be-1206 www.drugdiscoverytoday.comtween tumor and tumor-adjacent tissue in a small patient cohort
of breast and colorectal cancer patients [85].
Importantly, the effect of somatic mtDNA variants in the tumor
is based on the actual position and consequence of the variant(s)
combined with their heteroplasmy level within the tumor cells,
rather than the number of variants present. Only if variants have
an effect on the mitochondrial oxidative phosphorylation system
or another physiological process do they have the potential to
influence a patient’s cancer. Somatic variants that have no effect
on a physiological process are merely bystanders. Here, somatic
variants in the tumor might exert effects on tumor formation and/
or progression but might also induce the above-mentioned sus-
ceptibility to a regimen that induces severe oxidative stress in
mitochondria. Elaborating on this, not only somatic but also
germline mtDNA variants can exert effects on the oxidative phos-
phorylation system [86–88]. An illustrative example is that of
mtDNA haplogroups (containing certain mtDNA variants) with
decreased mitochondrial respiration system coupling efficiency
selected for in populations inhabiting colder climates, leading to
decreased ATP generation in favor of increased heat production.
Perhaps also certain mtDNA haplogroups exert increased or de-
creased response and/or risk of toxicity after certain anticancer
treatments.
Although it could be attractive at first sight because of the
multiple mtDNA copies and high mutation rate, the use of somatic
mtDNA variants in cancer lineage tracing or as a blood-circulating
biomarker is complicated given the large heterogeneity of mtDNA
variants within an individual. First, it is difficult (if not impossible)
to pinpoint the truly tumor-specific mtDNA variants, because of
the potential ‘founder effect’. Second, the dynamics of mtDNA
content can exert bottleneck effects on somatic mtDNA variants
when there is a (large) reduction in mtDNA content. Obviously,
such founder- or bottleneck-effects not only apply to differences
between the normal mammary epithelium but also to differences
between primary tumor and metastases or among metastases. For
now, it remains to be elucidated whether somatic mtDNA variants
have biological significance in tumor formation and progression,
or perhaps also in susceptibility to certain systemic treatment
regimens and can be of added value in the clinic.
Concluding remarks
Patients diagnosed at a higher age harbor more somatic mtDNA
variants in their primary tumor. Also, there is large heterogeneity
in somatic mtDNA variants within primary breast tumors. Al-
though mtDNA content in the primary breast tumor is not associ-
ated with any of the traditional clinicopathological markers, low
mtDNA levels in the primary breast tumor indicate a more aggres-
sive cancer, which appears more susceptible to anthracycline-
based regimens. The question remains how mtDNA genotype
(somatic and germline haplotype), heteroplasmy, expression
and content are affected in metastatic disease. Also, it remains
to be evaluated whether certain tumor-specific mtDNA variants, or
mtRNA expression associated with the subtype, are connected
with patient outcome and have any clinical importance.
The role of mtDNA variation in (breast) tumors has been largely
neglected. A complete picture should be obtained by studying
primary tumor and metastatic sites for their (somatic) mtDNA
variation. The effects these variations have on mitochondrial
Drug Discovery Today Volume 24, Number 5 May 2019 REVIEWSactivity should be assessed by functional assays, such as measure-
ment of the activity of the complexes of the oxidative phosphor-
ylation system, generation of ATP or ability to induce the
apoptotic pathway. When assessing such effects, one should also
take into account germline and cell-lineage-specific somatic vari-
ation, tissue distribution, the interactions between the nuclear
genome and the mitochondrial genome, and also tissue depen-dence on oxidative phosphorylation. Also, more insight is needed
into the role of mtDNA variations in healthy tissue on toxicities
and to what extent they might be associated with specific toxicities
and interindividual differences. Although the pivotal work from
Warburg describing the crucial role of mitochondria in cancer
already dates from a century ago, mitochondria and their mtDNA
deserve more attention now.SC
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